{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lauer D"],"funding":["Lungenliga Schweiz","Swiss National Science Foundation","Innosuisse - Schweizerische Agentur für Innovationsförderung","Inselspital, Universitätsspital Bern"],"pagination":["e181757"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11383602"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(15)"],"pubmed_abstract":["Antifibrotic therapy with nintedanib is the clinical mainstay in the treatment of progressive fibrosing interstitial lung disease (ILD). High-dimensional medical image analysis, known as radiomics, provides quantitative insights into organ-scale pathophysiology, generating digital disease fingerprints. Here, we performed an integrative analysis of radiomic and proteomic profiles (radioproteomics) to assess whether changes in radiomic signatures can stratify the degree of antifibrotic response to nintedanib in (experimental) fibrosing ILD. Unsupervised clustering of delta radiomic profiles revealed 2 distinct imaging phenotypes in mice treated with nintedanib, contrary to conventional densitometry readouts, which showed a more uniform response. Integrative analysis of delta radiomics and pr"],"journal":["JCI insight"],"pubmed_title":["Radioproteomics stratifies molecular response to antifibrotic treatment in pulmonary fibrosis."],"pmcid":["PMC11383602"],"funding_grant_id":["2019-06_644306","40927.1 IP-LS","13072","189737","316030"],"pubmed_authors":["Verleden SE","Heller M","Chabria M","Cereghetti GM","Brunner M","Uldry AC","Sarbu AC","Wang H","Klein K","Distler O","Ebner L","Gote-Schniering J","Funke-Chambour M","Magnin CY","Lauer D","Kolly LR","Gabrys HS","Maurer B","Tanadini-Lang S"],"additional_accession":[]},"is_claimable":false,"name":"Radioproteomics stratifies molecular response to antifibrotic treatment in pulmonary fibrosis.","description":"Antifibrotic therapy with nintedanib is the clinical mainstay in the treatment of progressive fibrosing interstitial lung disease (ILD). High-dimensional medical image analysis, known as radiomics, provides quantitative insights into organ-scale pathophysiology, generating digital disease fingerprints. Here, we performed an integrative analysis of radiomic and proteomic profiles (radioproteomics) to assess whether changes in radiomic signatures can stratify the degree of antifibrotic response to nintedanib in (experimental) fibrosing ILD. Unsupervised clustering of delta radiomic profiles revealed 2 distinct imaging phenotypes in mice treated with nintedanib, contrary to conventional densitometry readouts, which showed a more uniform response. Integrative analysis of delta radiomics and pr","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-05-04T06:51:48.618Z","creation":"2025-04-04T00:29:16.807Z"},"accession":"S-EPMC11383602","cross_references":{"pubmed":["39012714"],"doi":["10.1172/jci.insight.181757"]}}